RESUMO
Immuno-oncology treatments have revolutionized the therapeutic options for many types of cancer. The rapid clinical translation of the research results from the past decades has enabled the spread of immune checkpoint inhibitor therapy. In addition to cytokine treatments that modulate anti-tumor immunity, major advances have also been made in adoptive cell therapy, especially regarding the expansion and readministration of tumor-infiltrating lymphocytes. The study of genetically modified T cells is more advanced in hematological malignancies while the applicability in solid tumors is widely investigated. Neoantigens determine antitumor immunity, and neoantigen-based vaccines might contribute to therapy optimization. In this review, we present the diversity of immuno-oncology treatments both that are currently in use and those that are investigated in the research field.
